Stockscreener 앱 받기
33.41
1.09%
0.36
시간 외 거래:
33.41
전일 마감가:
$33.05
열려 있는:
$32.45
하루 거래량:
611.14K
Relative Volume:
0.94
시가총액:
$1.88B
수익:
$656.11M
순이익/손실:
$114.99M
주가수익비율:
13.58
EPS:
2.46
순현금흐름:
$212.78M
1주 성능:
-19.47%
1개월 성능:
-3.44%
6개월 성능:
+5.83%
1년 성능:
+28.90%
1일 변동 폭
$32.37
$33.58
1주일 범위
$31.02
$38.00
52주 변동 폭
$22.89
$41.61
하모니 바이오 Stock (HRMY) Company Profile
명칭
Harmony Biosciences Holdings Inc
전화
(484) 539-9800
주소
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
하모니 바이오 Stock (HRMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-21 | 개시 | Citigroup | Buy |
| 2024-01-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-20 | 개시 | BofA Securities | Neutral |
| 2022-10-14 | 업그레이드 | Janney | Neutral → Buy |
| 2022-10-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-04 | 개시 | Raymond James | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-03-29 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-14 | 개시 | Goldman | Neutral |
| 2020-09-14 | 개시 | Jefferies | Buy |
| 2020-09-14 | 개시 | Piper Sandler | Overweight |
모두보기
하모니 바이오 주식(HRMY)의 최신 뉴스
AlphaCentric Advisors LLC Reduces Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings - Yahoo Finance
HRMY vs. REGN: Which Stock Is the Better Value Option? - MSN
(HRMY) Trading Signals - Stock Traders Daily
Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Harmony Bio, The No. 1 Biotech Stock, Surges On Its 'High Quality' Beat - MSN
Harmony Biosciences Holdings Prices of Public Offering of Common Stock - citybiz
Harmony Biosciences chief commercial officer sells $870,018 in stock - Investing.com
Harmony Biosciences chief commercial officer sells $870,018 in stock By Investing.com - Investing.com Canada
Latham Advises Harmony Biosciences Holdings, Inc. in Public Offering of Common Stock by Selling Shareholders - ILW.com
HRMY Makes Notable Cross Below Critical Moving Average - Nasdaq
Harmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Estimate for HRMY Earnings - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2024 Earnings Call Transcript - Insider Monkey
Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next - Simply Wall St
Goldman Sachs maintains sell rating on HRMY stock with $28 target - Investing.com Canada
Top 5 US Stocks To Buy In October 2024 - Investing.com
Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Hi - GuruFocus.com
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders - StockTitan
Harmony’s Wakix Surpasses $2B in Revenue, Data Shows Promise for IH Treatment - Sleep Review
Goldman Sachs maintains sell rating on HRMY stock with $28 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald Raises Harmony Biosciences (NASDAQ:HRMY) Price Target to $58.00 - MarketBeat
Harmony Biosciences' (HRMY) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
Harmony Biosciences: Strong Q3 and Future Growth - MSN
Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Shares Gap DownHere's Why - MarketBeat
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt? - Simply Wall St
Harmony Biosciences stock hits 52-week high at $40.73 By Investing.com - Investing.com Australia
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ... - Investing.com Canada
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUA - GuruFocus.com
Harmony Biosciences initiates public stock offering by shareholders By Investing.com - Investing.com South Africa
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Large Decrease in Short Interest - MarketBeat
Harmony Biosciences initiates public stock offering by shareholders - Investing.com
Harmony Biosciences (HRMY) Commences 8M Share Offering by Selling Stockholders - StreetInsider.com
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders - Marketscreener.com
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript - Yahoo! Voices
Harmony Biosciences stock hits 52-week high at $40.73 - Investing.com
Harmony Biosciences (NASDAQ:HRMY) Shares Gap UpStill a Buy? - MarketBeat
Analyst Expectations For Harmony Biosciences's Future - Benzinga
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates - MSN
Needham & Company LLC Reiterates Buy Rating for Harmony Biosciences (NASDAQ:HRMY) - MarketBeat
Harmony Biosciences Q3 2024 Earnings: EPS of $0.79 Beats Estimat - GuruFocus.com
Harmony Biosciences : HRMY Q3 2024 Earnings Presentation FINAL - Marketscreener.com
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL - GuruFocus.com
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS - PR Newswire
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESUL - GuruFocus.com
Harmony Biosciences to Unveil Promising Late-Stage Pipeline at Investor Day - MSN
하모니 바이오 (HRMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):